10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Maro Ohanian et al.|The Lancet Haematology|2020Cited by 330
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsAhmad S. Alotaibi, Naval Daver, Musa Yılmaz et al.|Blood Cancer Discovery|2020Cited by 97
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disordersStephen O’Brien, MJ Keating, Razelle Kurzrock et al.|Blood|1994Cited by 63
<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemiaWei‐Ying Jen, Tapan M. Kadia, Guilin Tang et al.|British Journal of Haematology|2025Cited by 3